DK1382340T3 - Terapeutiske anvendelser af dehydroepiandrosteron til behandling af reduceret libido og osteoporose - Google Patents
Terapeutiske anvendelser af dehydroepiandrosteron til behandling af reduceret libido og osteoporoseInfo
- Publication number
- DK1382340T3 DK1382340T3 DK03019149T DK03019149T DK1382340T3 DK 1382340 T3 DK1382340 T3 DK 1382340T3 DK 03019149 T DK03019149 T DK 03019149T DK 03019149 T DK03019149 T DK 03019149T DK 1382340 T3 DK1382340 T3 DK 1382340T3
- Authority
- DK
- Denmark
- Prior art keywords
- dehydroepiandrosterone
- osteoporosis
- treatment
- therapeutic uses
- reduced libido
- Prior art date
Links
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 title 1
- 208000001132 Osteoporosis Diseases 0.000 title 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 title 1
- 229960002847 prasterone Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US561993A | 1993-01-19 | 1993-01-19 | |
US08/180,361 US5776923A (en) | 1993-01-19 | 1994-01-18 | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
EP94904546A EP0680327B1 (fr) | 1993-01-19 | 1994-01-19 | Procedes therapeutiques et systemes d'apport de deshydroepiandrosterone |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1382340T3 true DK1382340T3 (da) | 2006-08-14 |
Family
ID=21716809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03019149T DK1382340T3 (da) | 1993-01-19 | 1994-01-19 | Terapeutiske anvendelser af dehydroepiandrosteron til behandling af reduceret libido og osteoporose |
Country Status (10)
Country | Link |
---|---|
US (6) | US5776923A (fr) |
EP (1) | EP1382340B1 (fr) |
CN (3) | CN1954804A (fr) |
CA (1) | CA2154161C (fr) |
DK (1) | DK1382340T3 (fr) |
IL (5) | IL181017A0 (fr) |
MY (2) | MY157883A (fr) |
SK (1) | SK286664B6 (fr) |
UA (1) | UA73911C2 (fr) |
ZA (1) | ZA94372B (fr) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228852B1 (en) * | 1996-07-12 | 2001-05-08 | Carolyn V. Shaak | Transdermal application of naturally occurring steroid hormones |
AU8779898A (en) * | 1997-08-11 | 1999-03-01 | Weider Nutrition International, Inc. | Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors |
US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
ID27922A (id) * | 1998-06-11 | 2001-05-03 | Endorech Inc | KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL |
KR100302372B1 (ko) * | 1998-07-24 | 2001-12-05 | 박상철 | 골다공증예방및치료제로서의디히드로에피안드로스테론유도체 |
US6726673B1 (en) * | 1999-05-24 | 2004-04-27 | Zars, Inc. | Methods and apparatus for improved administration of testosterone pharmaceuticals |
US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
US7045513B1 (en) * | 1999-03-18 | 2006-05-16 | Genelabs Technologies, Inc. | DHEA composition and method |
CN100544726C (zh) | 1999-03-18 | 2009-09-30 | 基因实验室技术公司 | Dhea制剂及方法 |
EP1187618A1 (fr) * | 1999-06-04 | 2002-03-20 | The General Hospital Corporation | Formulations pharmaceutiques pour traiter des femmes en periode de postmenopause et de perimenopause, et leur utilisation |
EP1955700B9 (fr) | 1999-09-30 | 2011-09-07 | Harbor BioSciences, Inc. | Traitement thérapeutique des maladies liées au récepteur androgène |
FR2799645B1 (fr) * | 1999-10-13 | 2004-04-30 | Oreal | Utilisation de la dhea ou de ses precurseurs ou derives metaboliques comme depigmentant |
US6846496B1 (en) | 1999-10-15 | 2005-01-25 | Orion Corporation | Treatment of osteoporosis |
US6605591B1 (en) | 1999-11-12 | 2003-08-12 | Genelabs Technologies, Inc. | Treatment of subnormal bone mineral density |
FR2803519B1 (fr) * | 2000-01-12 | 2002-03-22 | Assist Publ Hopitaux De Paris | Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs et de ses derives pour ameliorer l'aspect papyrace de la peau |
KR20020073566A (ko) * | 2000-01-28 | 2002-09-27 | 앙도르쉐르슈 인코포레이티드 | 에스트로겐과 배합된 선택적인 에스트로겐 수용체 조절자 |
AU2001241779A1 (en) | 2000-02-25 | 2001-09-03 | Hollis-Eden Pharmaceuticals, Inc. | Method of treatment of prostate cancer |
FR2807323A1 (fr) | 2000-04-10 | 2001-10-12 | Oreal | Composition, notamment cosmetique, renfermant un steroide et un 2-alkyl alcanol ou un ester |
US7067557B2 (en) * | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
JP2003534375A (ja) | 2000-05-26 | 2003-11-18 | フィッチ,ハリー | 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法 |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
EP1315502B1 (fr) * | 2000-08-30 | 2010-03-17 | Unimed Pharmaceuticals, LLC | Methode pour traiter la dyserection et augmenter la libido chez l'homme |
PL360992A1 (en) * | 2000-08-30 | 2004-09-20 | Unimed Pharmaceuticals,Inc. | Method of increasing testosterone and related steroid concentrations in women |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
SI1347764T1 (sl) * | 2000-12-22 | 2007-06-30 | August Wolff Gmbh & Co Kg Arzenmittel Dr | Gelni sestavek na alkoholni osnovi za zdravljenje hipogonadizma s trans-skrotalno aplikacijo |
US20030119800A1 (en) * | 2001-06-18 | 2003-06-26 | Manolagas Stavros C. | Bone anabolic compounds and methods of use |
RU2297218C2 (ru) * | 2001-07-09 | 2007-04-20 | Зонаджен, Инк. | Способы и материалы для лечения тестостероновой недостаточности у мужчин |
US7173064B2 (en) * | 2001-07-09 | 2007-02-06 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy |
US7737185B2 (en) * | 2001-07-09 | 2010-06-15 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene |
FR2827764B1 (fr) * | 2001-07-27 | 2005-08-19 | Oreal | Composition, notamment cosmetique, renfermant un steroide et un glycol |
FR2828100B1 (fr) * | 2001-08-02 | 2004-09-24 | Galderma Res & Dev | Composition de type emulsion inverse contenant de la dhea et/ou ses precurseurs ou derives, et ses utilisations en cosmetique et en dermatologie |
EP1350541A1 (fr) * | 2002-04-04 | 2003-10-08 | Jenapharm GmbH & Co. KG | Emploi de déhydro-épiandrosterone et d'un dérivé d'estradiol pour préparer un médicament pour le traitement des troubles climactériques de la postménopause |
WO2003090754A1 (fr) * | 2002-04-23 | 2003-11-06 | Sahltech I Göteborg AB | Utilisation de la dhea pour le traitement de l'hypopituitarisme chez la femme |
KR100538386B1 (ko) * | 2002-08-26 | 2005-12-27 | 메타볼랩(주) | Il-1 관련 질병 또는 질환의 치료용 약제학적 조성물 |
CN1726020A (zh) * | 2002-10-16 | 2006-01-25 | Gtx公司 | 用sarm治疗老年男性雄激素缺乏(adam)相关的疾病 |
US20060276539A1 (en) * | 2002-10-16 | 2006-12-07 | Dalton James T | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS |
US20040087564A1 (en) * | 2002-10-31 | 2004-05-06 | Wright D. Craig | Delivery composition and method |
PT1670433E (pt) | 2003-10-10 | 2012-02-08 | Ferring Bv | Fórmula farmacológica transdérmica para a minimização de resíduos na pele |
US20050181057A1 (en) * | 2004-02-13 | 2005-08-18 | Rosenberg Paul K. | Vaginal lubricant |
US20050239826A1 (en) * | 2004-04-14 | 2005-10-27 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
MX2007000050A (es) * | 2004-07-14 | 2007-07-10 | Repros Therapeutics Inc | Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado. |
CN106038572A (zh) | 2004-10-20 | 2016-10-26 | 恩多研究公司 | 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍 |
BRPI0606528A8 (pt) * | 2005-02-04 | 2018-03-13 | Repros Therapeutics Inc | composição para uso no fabrico de medicamentos de tratamento da infertilidade masculina e uso da mesma |
JP5785680B2 (ja) * | 2005-03-22 | 2015-09-30 | リプロス セラピューティクス インコーポレイテッド | トランス−クロミフェン用の投与レジメン |
US7473687B2 (en) * | 2005-03-24 | 2009-01-06 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
EP2431042B1 (fr) * | 2005-03-24 | 2013-06-26 | Emory University | Procédés pour le traitement des blessures du système nerveux central via un protocole d'administration biseauté |
CN101217874B (zh) * | 2005-04-12 | 2012-06-06 | 优尼麦德药物股份有限公司 | 治疗或预防骨退化或骨质疏松症的方法 |
US8084446B2 (en) | 2005-04-26 | 2011-12-27 | Eric Marchewitz | Use of DHEA derivatives for enhancing physical performance |
WO2006125642A1 (fr) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Procedes et dispositifs d'application transdermique ou transmucosale de testosterone |
SI1937276T1 (sl) | 2005-10-12 | 2013-04-30 | Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road | Izboljšani testosteronski gel in postopek uporabe |
JP2009519926A (ja) * | 2005-12-16 | 2009-05-21 | ライル コーポレート ディベロップメント インコーポレーテッド | エストロゲンの非全身性膣投与による膣組織の再生 |
CA2646667C (fr) | 2006-04-21 | 2014-03-11 | Antares Pharma Ipl Ag | Methode de traitement des bouffees de chaleur par des preparations transdermiquea ou transmucosiques |
US8268806B2 (en) * | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
AU2012204083C1 (en) * | 2007-08-10 | 2015-02-05 | Myriel Pharmaceuticals, Llc | DHEA compositions for treating menopause |
CA2702710C (fr) | 2007-10-16 | 2013-05-07 | Repros Therapeutics, Inc. | Traitement d'un syndrome metabolique par trans-clomiphene |
US20100317635A1 (en) * | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
WO2013012430A1 (fr) * | 2011-07-19 | 2013-01-24 | Riepl Michael S | Gel à libération contrôlée bioadhésif de dhea |
UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
US9320744B2 (en) | 2011-10-19 | 2016-04-26 | Dhea Llc | DHEA bioadhesive controlled release gel |
CA2860133C (fr) | 2011-12-29 | 2016-10-11 | Universidad De Chile | Anneau vaginal comprenant de la dhea ou du sulfate de dhea et eventuellement un agent modulateur de la liberation du principe actif, utile pour augmenter la reserve ovarienne chezles femmes et pour attenuer les symptomes associes a la menopause |
CN102631677A (zh) * | 2012-04-19 | 2012-08-15 | 中国农业大学 | 一种预防和/或治疗动脉粥样硬化的药物组合物 |
CN104994877A (zh) | 2012-11-02 | 2015-10-21 | 利普生物药剂公司 | 用于癌症治疗的反式-克罗米芬 |
US20150313956A1 (en) * | 2014-05-05 | 2015-11-05 | Napier Consulting Llc | Compositions and methods for hair growth |
CN115554403B (zh) * | 2022-08-16 | 2024-03-08 | 山东大学 | 类固醇激素dhea作为受体adgrg2激动剂配体的应用 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK122125B (da) * | 1967-10-04 | 1972-01-24 | Schering Ag | Analogifremgangsmåde til fremstilling af terapeutisk aktive carboxylsyreestere af 3β-hydroxy-5-androstan-17-on(dehydroepiandrosteron) med 7-11 carbonatomer i esterresten. |
US3551554A (en) * | 1968-08-16 | 1970-12-29 | Crown Zellerbach Corp | Enhancing tissue penetration of physiologically active agents with dmso |
US3472931A (en) * | 1969-01-17 | 1969-10-14 | Foster Milburn Co | Percutaneous absorption with lower alkyl amides |
US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US3742951A (en) * | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
JPS505372A (fr) * | 1973-05-30 | 1975-01-21 | ||
US4006218A (en) * | 1974-07-08 | 1977-02-01 | Johnson & Johnson | Potentiated medicaments |
US3989816A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
US4405616A (en) * | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
DE2534911C2 (de) * | 1975-08-01 | 1985-04-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von 5-Androsten-17-on-Derivaten |
US4213978A (en) * | 1978-12-05 | 1980-07-22 | Interx Research Corporation | Anti-acne and anti-seborrhea prodrug derivatives of progesterone |
US4425339A (en) * | 1981-04-09 | 1984-01-10 | Syntex (U.S.A.) Inc. | Treatment of menopausal symptoms |
FR2518879A1 (fr) * | 1981-12-30 | 1983-07-01 | Besins Jean | Medicament a base d'oestradiol pour le traitement de la pathologie menopausique |
US4496556A (en) * | 1982-08-16 | 1985-01-29 | Norman Orentreich | Topical applications for preventing dry skin |
US4542129A (en) * | 1982-08-16 | 1985-09-17 | Norman Orentreich | DHEA Formulations and methods for treating dry skin |
SE8303031D0 (sv) * | 1983-05-30 | 1983-05-30 | Leo Ab | Improved steroid esters preparation |
US4518595A (en) * | 1983-07-19 | 1985-05-21 | The Jackson Laboratory | Method for treating diabetes using DHEA compounds |
DE3333240A1 (de) * | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur transdermalen applikation von arzneimittelwirkstoffen |
US4725439A (en) * | 1984-06-29 | 1988-02-16 | Alza Corporation | Transdermal drug delivery device |
US4624665A (en) * | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
US4568343A (en) * | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4812447A (en) * | 1985-10-22 | 1989-03-14 | City Of Hope | Method for the treatment of nervous system degeneration |
US4666441A (en) * | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
IE60941B1 (en) * | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
US4816258A (en) * | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
NL194728C (nl) * | 1987-04-16 | 2003-01-07 | Hollis Eden Pharmaceuticals | Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan. |
US4835147A (en) * | 1987-05-06 | 1989-05-30 | City Of Hope | Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction |
US5051260A (en) * | 1987-07-16 | 1991-09-24 | The Regents Of The University Of California | Method and composition for enhancing the cutaneous penetration of pharmacologically active agents |
US5064654A (en) * | 1989-01-11 | 1991-11-12 | Ciba-Geigy Corporation | Mixed solvent mutually enhanced transdermal therapeutic system |
US5162037A (en) * | 1988-04-01 | 1992-11-10 | Whitson Laboratories, Inc. | Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration |
US5047244A (en) * | 1988-06-03 | 1991-09-10 | Watson Laboratories, Inc. | Mucoadhesive carrier for delivery of therapeutical agent |
WO1990006120A1 (fr) * | 1988-12-01 | 1990-06-14 | Schering Corporation | Compositions d'administration transdermique d'estradiol |
IE62715B1 (en) * | 1989-03-10 | 1995-02-22 | Endorecherche Inc | Combination therapy for treatment of estrogen sensitive diseases |
US4978532A (en) * | 1989-08-11 | 1990-12-18 | Pharmedic Co. | Dosage form for administration of dehydroepiandrosterone |
US5116828A (en) * | 1989-10-26 | 1992-05-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of osteoporosis |
US5071644A (en) * | 1990-08-07 | 1991-12-10 | Mediventures, Inc. | Topical drug delivery with thermo-irreversible gels |
ZA924811B (en) * | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
HU222501B1 (hu) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
-
1994
- 1994-01-18 US US08/180,361 patent/US5776923A/en not_active Expired - Lifetime
- 1994-01-19 IL IL181017A patent/IL181017A0/en unknown
- 1994-01-19 ZA ZA94372A patent/ZA94372B/xx unknown
- 1994-01-19 DK DK03019149T patent/DK1382340T3/da active
- 1994-01-19 CA CA002154161A patent/CA2154161C/fr not_active Expired - Lifetime
- 1994-01-19 IL IL181018A patent/IL181018A/en not_active IP Right Cessation
- 1994-01-19 CN CNA2006100956345A patent/CN1954804A/zh active Pending
- 1994-01-19 IL IL181016A patent/IL181016A0/en unknown
- 1994-01-19 MY MYPI20064307A patent/MY157883A/en unknown
- 1994-01-19 UA UA95073333A patent/UA73911C2/uk unknown
- 1994-01-19 EP EP03019149A patent/EP1382340B1/fr not_active Expired - Lifetime
- 1994-01-19 SK SK5103-2006A patent/SK286664B6/sk not_active IP Right Cessation
- 1994-01-19 MY MYPI94000149A patent/MY134585A/en unknown
- 1994-01-19 IL IL181015A patent/IL181015A/en not_active IP Right Cessation
- 1994-01-19 CN CNA2008101680721A patent/CN101444519A/zh active Pending
- 1994-01-19 CN CN2011101909338A patent/CN102357247A/zh active Pending
- 1994-01-19 IL IL181019A patent/IL181019A0/en unknown
-
1995
- 1995-06-07 US US08/480,592 patent/US5824671A/en not_active Expired - Fee Related
- 1995-06-07 US US08/488,392 patent/US5780460A/en not_active Expired - Lifetime
- 1995-06-07 US US08/488,391 patent/US5922700A/en not_active Expired - Fee Related
- 1995-06-07 US US08/480,591 patent/US5728688A/en not_active Expired - Lifetime
-
1997
- 1997-11-13 US US08/969,197 patent/US5955455A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
SK286664B6 (sk) | 2009-03-05 |
CN101444519A (zh) | 2009-06-03 |
CA2154161A1 (fr) | 1994-08-04 |
ZA94372B (en) | 1995-07-19 |
US5824671A (en) | 1998-10-20 |
MY134585A (en) | 2007-12-31 |
US5776923A (en) | 1998-07-07 |
MY157883A (en) | 2016-08-01 |
IL181018A (en) | 2012-07-31 |
US5728688A (en) | 1998-03-17 |
UA73911C2 (en) | 2005-10-17 |
US5922700A (en) | 1999-07-13 |
IL181017A0 (en) | 2007-07-04 |
EP1382340B1 (fr) | 2006-04-05 |
CA2154161C (fr) | 2006-12-12 |
CN1954804A (zh) | 2007-05-02 |
US5955455A (en) | 1999-09-21 |
IL181019A0 (en) | 2007-07-04 |
EP1382340A1 (fr) | 2004-01-21 |
US5780460A (en) | 1998-07-14 |
IL181016A0 (en) | 2007-07-04 |
IL181015A0 (en) | 2007-07-04 |
IL181015A (en) | 2012-12-31 |
CN102357247A (zh) | 2012-02-22 |
IL181018A0 (en) | 2007-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1382340T3 (da) | Terapeutiske anvendelser af dehydroepiandrosteron til behandling af reduceret libido og osteoporose | |
DK0830864T3 (da) | Kombinationsbehandling til behandling af psykoser | |
BR9407869A (pt) | Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose | |
NO971015D0 (no) | Forbindelser og metoder for behandling av cancer | |
IS5407A (is) | Ný notkun fyrir búdesóníð og formóteról | |
DK0621042T3 (da) | Kirurgisk forbinding og adhæsivsammensætning dertil | |
DE69401549D1 (de) | Plasma-Behandlungsgerät | |
ZA929758B (en) | Methods for the treatment of osteoporosis using biphosphonates and parathyroid hormone | |
DK64592D0 (da) | Peptider til terapeutisk behandling | |
NO932915D0 (no) | Mikroporoest krystallinsk silikoaluminofosfat og fremgangsmaate for fremstilling av dette | |
IS4805A (is) | Aðferð til meðhöndlunar og lyfjasamsetning | |
IS4466A (is) | Samsetning og meðhöndlun fyrir heila- og mænusigg | |
IL136110A0 (en) | Methods and compositions for the treatment of psoriasis | |
DK1041985T3 (da) | Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme | |
NO972426D0 (no) | Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose | |
GB9808936D0 (en) | Combination therapy for the prevention and treatment of osteoporosis | |
NO961226D0 (no) | Blandinger for forebyggelse og behandling av viralinduserte tumorer | |
AU7105498A (en) | Combination therapy for the prevention and treatment of osteoporosis | |
DK1017388T3 (da) | Farmaceutiske præparater indeholdende ibuprofen og domperidon til behandling af migræne | |
NO20001758D0 (no) | Fremgangsmåter og blandinger for behandling av leddgikt | |
IL115224A0 (en) | Preparations for use in the treatment of osteoporosis | |
DK0693912T3 (da) | Apparat til medicinsk behandling | |
DK0670721T3 (da) | Lægemiddel til behandling og forebyggelse af knogle- og ledsygdomme | |
DK0981349T3 (da) | 5-alfa-pregnan-3-beta-ol-20-on-sulfat til behandling af tumorer og CNS sygdomme | |
NO920546L (no) | Fremgangsmaate for flussbehandling og flussvedheftende komponent |